Results for this period
Interim period (second quarter)1 January 2026–30 June 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Revenue from test products declined because the scale of the COVID-19 outbreak decreased, testing shifted from genetic tests to antigen tests, and the scale of outbreaks of other infectious diseases contracted. Lower revenue from COVID-19 genetic test kits and products for other infectious diseases was the primary factor behind the decline in operating profit.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 January 2026–30 June 2026 |
| Net Sales | ¥3,533 million (YoY -11.1%) |
| Operating profit | ¥996 million (YoY -32.5%) |
| Ordinary income | ¥1,111 million (YoY -20.5%) |
| Profit attributable to owners of the parent | ¥822 million (YoY -19.4%) |
| Net income per share | ¥43.18 |
| Equity ratio | End of the current fiscal period 88.4% / End of previous period 83.5% |
| Total assets | ¥20,986 million |
| Net assets | ¥18,554 million |
| Cash flows from operating activities | ¥3,261 million |
| Cash flows from investing activities | ¥6,880 million |
| Cash flows from financing activities | ¥-968 million |
| Cash and cash equivalents at end of period | ¥11,433 million |
| Full-year earnings forecast | Net Sales ¥11,428 million (YoY +1.5%) / Operating profit ¥4,414 million (YoY -5.0%) / Ordinary income ¥4,437 million (YoY -6.3%) / Net income ¥3,220 million (YoY -6.0%) |
| Annual Dividend Forecast | ¥100 → ¥100（0.0%） |
| Depreciation and amortization | ¥139 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 19,051,200 shares |
| Treasury Shares at Period-End | 2,550 shares |
| Factors Behind Changes in Business Performance | Revenue from test products declined because the scale of the COVID-19 outbreak decreased, testing shifted from genetic tests to antigen tests, and the scale of outbreaks of other infectious diseases contracted. Lower revenue from COVID-19 genetic test kits and products for other infectious diseases was the primary factor behind the decline in operating profit. |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue declined because the scale of the COVID-19 outbreak was contained compared with the previous year, testing shifted from genetic tests to antigen tests, and other infectious diseases did not spread on the same scale as in the previous year. Operating profit declined mainly because of lower revenue from COVID-19 genetic test kits and products for other infectious diseases.